USPTO serial 98922836
MAVATAR
Reviewed by CopyMark Law Group
Status 730Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- PARADEWELAI, BENJI YUEN
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with MAVATAR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,844*
Plus Government fees of $900
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Helsingborg, SE
Helsingborg, SE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karen Kreider Gaunt
Karen Kreider Gaunt Dinsmore & Shohl LLP255 E. 5th Street, Suite 1900Cincinnati, OH 45202United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, namely, medical diagnostic reagents for identifying treatment response in oncology and inflammatory diseases; diagnostic biomarker reagents for medical purposes. | ACTIVE | — |
| 009 | Downloadable software for medical diagnostics; downloadable databases in the fields of medical information, medical research, medical diagnostics and medical treatments; Downloadable artificial intelligence software that integrates model data with biomedical data of patients to create a digital twin of a patient; Downloadable artificial intelligence software that integrates model data with biomedical data to create a digital twin of a patient; Downloadable software for research and analysis of medical and biomedical data; Downloadable software for gathering, compiling, analyzing, authenticating, validating, controlling, protecting, exchanging, and modifying genetic, genomic, molecular, and biomarker data; Downloadable software for comparing patient biomarker data against genetic, proteomic, and transcriptomic database; Downloadable software for the collection, editing, organizing, modifying, transmission, storage, and sharing of data and information for use by pharmaceutical companies and healthcare providers; Downloadable software for developing drugs by simulating patient responses to medications; Downloadable software for predicting patient treatment response; downloadable databases containing biomedical data. | ACTIVE | — |
| 035 | Compiling of biomedical data into computer databases for business purposes; providing online business organization workflow information to pharmaceutical companies to enable streamlining of drug discovery and development. | ACTIVE | — |
| 038 | Provision of access to databases; Provision of access to databases containing biomedical data. | ACTIVE | — |
| 042 | Research and development services in the field of medical preparations; Medical and scientific research and development services in the fields of precision medicine and pharmaceutical drug development; biomedical research services; Platform as a service (PAAS) featuring computer software using artificial intelligence (AI) for integrating model data with biomedical data of patients to create a digital twin of a patient; Software as a service (SAAS) services featuring software for integrating model data with biomedical data of a patient to create a digital twin of a patient; Platform as a service (PAAS) featuring computer software using artificial intelligence (AI) for integrating model data with biomedical data to create a digital twin of a patient; Software as a service (SAAS) services featuring software for integrating model data with biomedical data to create a digital twin of a patient; Platform as a service (PAAS) featuring computer software using artificial intelligence (AI) for research and analysis of medical and biomedical data; Software as a service (SAAS) services featuring software for research and analysis of medical and biomedical data; Platform as a service (PAAS) featuring computer software using artificial intelligence (AI) for gathering, compiling, analyzing, authenticating, validating, controlling, protecting, exchanging, and modifying genetic, genomic, molecular and biomarker data; Software as a service (SAAS) services featuring software for gathering, compiling, analyzing, authenticating, validating, controlling, protecting, exchanging and modifying genetic, genomic, molecular and biomarker data; Platform as a service (PAAS) featuring computer software using artificial intelligence (AI) for comparing patient biomarker data against genetic, proteomic, and transcriptomic database; Software as a service (SAAS) services featuring software for comparing patient biomarker data against genetic, proteomic, and transcriptomic database; Platform as a service (PAAS) featuring computer software using artificial intelligence (AI) for the collection, editing, organizing, modifying, transmission, storage, and sharing of data and information for use by pharmaceutical companies and healthcare providers; Software as a service (SAAS) services featuring software for the collection, editing, organizing, modifying, transmission, storage, and sharing of data and information for use by pharmaceutical companies and healthcare providers; Platform as a service (PAAS) featuring computer software using artificial intelligence (AI) for developing drugs by simulating patient responses to medications; Software as a service (SAAS) services featuring software for developing drugs by simulating patient responses to medications; Platform as a service (PAAS) featuring computer software using artificial intelligence (AI) for predicting patient treatment response; Software as a service (SAAS) services featuring software for predicting patient treatment response; providing medical and scientific research information; information services relating to pharmaceutical drug development; information services provided via the internet, namely providing information to pharmaceutical companies to streamline drug discovery and development; providing online pharmaceutical drug research information via the internet to pharmaceutical companies to enable streamlining of drug discovery and development; providing scientific analysis related to genetic, genomic, molecular, and biomarker data; software as a service (SAAS) services featuring software that enables users to access, track, monitor and generate informational reports based upon results of genetic, genomic, molecular, and biomarker data. | ACTIVE | — |
| 044 | Healthcare information services; healthcare consultancy services; healthcare services; Medical information services provided via the Internet, namely providing personalized treatment suggestions to medical professionals tailored after their patients' health profile; Medical information services provided via the Internet, namely providing medical information to pharmaceutical companies to streamline drug discovery and development; Provision of medical information from online databases. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by AB MAvatar
- Other trademarks owned by AB MAvatar
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 038
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MAVATAR
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 30, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 29, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 29, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 29, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 17, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 23, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 23, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 17, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 1, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 1, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 1, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 1, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 1, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 25, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 25, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 25, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 25, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 25, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 25, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 21, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 21, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 21, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 16, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 16, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 16, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 10, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 28, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 26, 2024 | NWAP | NEW APPLICATION ENTERED | — |